• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk.

作者信息

Jindal Ankur, Kumar Manoj

机构信息

Department of Hepatology and Liver Transplantation, Institute of Liver and Biliary Sciences, D1 Vasant Kunj, New Delhi, 110070, India.

出版信息

Hepatol Int. 2025 Aug;19(4):701-703. doi: 10.1007/s12072-025-10874-8. Epub 2025 Jul 15.

DOI:10.1007/s12072-025-10874-8
PMID:40665102
Abstract
摘要

相似文献

1
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk.替诺福韦艾拉酚胺相关的高脂血症和心血管风险。
Hepatol Int. 2025 Aug;19(4):701-703. doi: 10.1007/s12072-025-10874-8. Epub 2025 Jul 15.
2
Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis.替诺福韦艾拉酚胺在高脂血症和心血管疾病背景下的安全性：一项全国性分析。
Hepatol Int. 2025 Mar 8. doi: 10.1007/s12072-025-10809-3.
3
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-human, phase 1 trial.一种每年一次的替诺福韦艾拉酚胺硅酮皮下植入剂在南非女性中的安全性、耐受性和药代动力学：一项分为两部分的、随机、安慰剂对照、双盲、首次人体1期试验。
Lancet HIV. 2025 Aug;12(8):e556-e567. doi: 10.1016/S2352-3018(25)00079-7. Epub 2025 Jun 27.
4
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.恩曲他滨和丙酚替诺福韦艾拉酚胺与恩曲他滨和替诺福韦二吡呋酯用于 HIV-1 暴露前预防的长期安全性和有效性：一项随机、双盲、安慰剂对照、3 期临床试验的第 96 周结果。
Lancet HIV. 2021 Jul;8(7):e397-e407. doi: 10.1016/S2352-3018(21)00071-0.
5
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial.使用丙酚替诺福韦进行早期抗病毒治疗以预防慢性乙型肝炎且病毒血症为中度或高度的成人发生严重临床不良事件（ATTENTION）：一项随机对照试验的中期结果
Lancet Gastroenterol Hepatol. 2025 Apr;10(4):295-305. doi: 10.1016/S2468-1253(24)00431-X. Epub 2025 Feb 3.
6
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.多替拉韦与拉米夫定维持治疗对比比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺用于HIV感染者（PASO-DOBLE）：一项随机、多中心、开放标签、非劣效性试验的48周结果
Lancet HIV. 2025 Jul;12(7):e473-e484. doi: 10.1016/S2352-3018(25)00105-5. Epub 2025 Jun 7.
7
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study.在病毒学抑制的慢性乙型肝炎合并肾或肝功能损害患者中换用替诺福韦艾拉酚胺：一项开放标签、多中心、2 期研究的第 96 周最终结果。
Lancet Gastroenterol Hepatol. 2024 Aug;9(8):718-733. doi: 10.1016/S2468-1253(24)00096-7. Epub 2024 Jun 17.
8
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.在接受整合酶抑制剂、替诺福韦艾拉酚胺或两者联合治疗的人群中，体重指数变化与高血压和血脂异常风险的相关性与其他当代抗逆转录病毒治疗方案相比：来自 RESPOND 联盟队列的多中心前瞻性观察研究。
Lancet HIV. 2024 May;11(5):e321-e332. doi: 10.1016/S2352-3018(23)00328-4. Epub 2024 Apr 12.
9
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.在TANGO研究中，至第196周，从基于替诺福韦艾拉酚胺的三药或四药方案转换为多替拉韦/拉米夫定二药方案的持久疗效。
J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003395.
10
Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.比较替诺福韦艾拉酚胺和恩替卡韦对乙型肝炎表面抗原水平下降的影响。
Eur J Gastroenterol Hepatol. 2021 Feb 1;32(2):255-260. doi: 10.1097/MEG.0000000000001733.

本文引用的文献

1
Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors.肝脏免疫相关不良事件提高了接受免疫检查点抑制剂治疗的恶性肿瘤患者的总生存率。
Hepatol Int. 2025 Apr 8. doi: 10.1007/s12072-025-10825-3.
2
Impact of Tenofovir Alafenamide on Lipid Profiles in Chronic Hepatitis B Patients: Systematic Review and Meta-Analysis.替诺福韦艾拉酚胺对慢性乙型肝炎患者血脂谱的影响：系统评价与荟萃分析
J Med Virol. 2025 Apr;97(4):e70331. doi: 10.1002/jmv.70331.
3
Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis.
一线核苷（酸）类似物对慢性乙型肝炎患者血脂谱的影响：网络荟萃分析。
Eur J Clin Pharmacol. 2024 Mar;80(3):335-354. doi: 10.1007/s00228-023-03616-y. Epub 2024 Jan 10.
4
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide.富马酸替诺福韦二吡呋酯或替诺福韦艾拉酚胺治疗的慢性乙型肝炎患者的心血管风险。
Clin Mol Hepatol. 2024 Jan;30(1):49-63. doi: 10.3350/cmh.2023.0328. Epub 2023 Nov 20.
5
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks.替诺福韦艾拉酚胺或替诺福韦酯治疗 96 周的慢性乙型肝炎患者的动脉粥样硬化性心血管疾病风险特征。
Aliment Pharmacol Ther. 2024 Jan;59(2):217-229. doi: 10.1111/apt.17764. Epub 2023 Oct 31.
6
Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.富马酸替诺福韦二吡呋酯换用替诺福韦艾拉酚胺后慢性乙型肝炎患者的体重增加和代谢紊乱。
Aliment Pharmacol Ther. 2024 Jan;59(2):230-238. doi: 10.1111/apt.17765. Epub 2023 Oct 16.
7
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.替诺福韦艾拉酚胺治疗慢性乙型肝炎患者发生血脂异常的风险：系统评价和荟萃分析。
Hepatol Int. 2023 Aug;17(4):860-869. doi: 10.1007/s12072-023-10528-7. Epub 2023 Apr 26.
8
Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.替诺福韦艾拉酚胺用于核苷（酸）类似物经治慢性乙型肝炎患者：一项真实世界、多中心队列研究的 144 周结果。
Aliment Pharmacol Ther. 2022 Aug;56(4):713-722. doi: 10.1111/apt.17107. Epub 2022 Jun 23.
9
Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.富马酸替诺福韦二吡呋酯通过肝 CD36/PPAR-α 激活调节乙型肝炎病毒感染中的脂质代谢。
J Gastroenterol. 2021 Feb;56(2):168-180. doi: 10.1007/s00535-020-01750-3. Epub 2020 Nov 19.
10
Tenofovir alafenamide does not inhibit mitochondrial function and cholesterol biosynthesis in human T lymphoblastoid cell line.替诺福韦艾拉酚胺不会抑制人 T 淋巴母细胞系中的线粒体功能和胆固醇生物合成。
Antiviral Res. 2020 Nov;183:104948. doi: 10.1016/j.antiviral.2020.104948. Epub 2020 Sep 24.